ArticleFrontiers in pharmacology2016
Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol.
Article in Frontiers in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Cannabis and cannabinoid use in autism spectrum disorder: a systematic review.Trends in psychiatry and psychotherapy · 2022Pooled it
- Pooled it
- A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.CNS drugs · 2018Pooled it
- Cannabidiol at the crossroads: panacea, placebo, or problem?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Research and Clinical Practice Involving the Use ofPharmaceuticals (Basel, Switzerland) · 2024Review
- Article
- Cannabidiol Modifies the Glutamate Over-Release in Brain Tissue of Patients and Rats with Epilepsy: A Pilot Study.Biomedicines · 2023Article
- Decoding the Postulated Entourage Effect of MedicinalBiomedicines · 2023Review
- The effect of cannabidiol on seizure features and quality of life in drug-resistant frontal lobe epilepsy patients: a triple-blind controlled trial.Frontiers in neurology · 2023Article
- Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario.Journal of cannabis research · 2022Review
- Cannabinoids-Characteristics and Potential for Use in Food Production.Molecules (Basel, Switzerland) · 2021Review
- Efficacy and safety of paediatric medicinal cannabis use: A scoping review.Paediatrics & child health · 2021Article
- Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.Advances in experimental medicine and biology · 2021Review
- Review
- Oral Cannabidiol Does Not Convert to ΔCannabis and cannabinoid research · 2020Article
- Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products.Therapeutic advances in psychopharmacology · 2020Review
- Phenotype-Based Screening of Synthetic Cannabinoids in a Dravet Syndrome Zebrafish Model.Frontiers in pharmacology · 2020Article
- Navigating Blind in the Green Rush: Clinical Considerations and Harm Reduction Practices for Cannabis.Current drug research reviews · 2019Article
- A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis.Scientific reports · 2018Article
- Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.CNS drugs · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with treatment-resistant epilepsy. However, these compounds are not yet registered as medicines by regulatory agencies. We describe the cases of two children with treatment-resistant epilepsy (Case A with left frontal dysplasia and Case B with Dravet Syndrome) with initial symptom improvement after the introduction of CBD extracts followed by seizure worsening after a short time. The children presented typical signs of intoxication by Δ9-THC (inappropriate laughter, ataxia, reduced attention, and eye redness) after using a CBD-enriched extract. The extract was replaced by the same dose of purified CBD with no Δ9-THC in both cases, which led to improvement in intoxication signs and seizure remission. These cases support pre-clinical and preliminary clinical evidence suggesting that CBD may be effective for some patients with epilepsy. Moreover, the cases highlight the need for randomized clinical trials using high-quality and reliable substances to ascertain the safety and efficacy of cannabinoids as medicines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.